Author:
Žigon-Branc Sara,Barlič Ariana,Jeras Matjaž
Reference49 articles.
1. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651-665. DOI: 10.1182/blood-2011-04-325225
2. Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. International Journal of Molecular Sciences. 2018;19:1442. DOI: 10.3390/ijms19051442
3. Yan L, Hu R, Tu S, Cheng W-J, Zheng Q, Wang J-W, et al. Establishment of a cell model for screening antibody drugs against rheumatoid arthritis with ADCC and CDC. International Journal of Clinical and Experimental Medicine. 2015;8:20065-20071
4. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents—Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56-63. DOI: 10.1016/j.cyto.2016.08.014
5. Chen X, Oppenheim JJ. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Science Signaling. 2017;10:eaal2328. DOI: 10.1126/scisignal.aal2328